Tuesday 9 December 2025
  • About
  • Contact
  • Login
  • VC & Investment
  • M&A
  • AI
  • Podcasts
  • News
    • Pharmaceutical News
    • Biotechnology News
    • Generics News
    • Biosimilars news
    • In Brief
    • Legal
    • Company Pages
    • In The Boardroom
  • Insights
    • Analysis
    • Special Report
    • Interviews
    • Expert View
    • From Our Correspondent
    • One To Watch Companies
    • Digital Pharma
    • Pharma Leaders
  • Regulatory
    • FDA
    • EMA
    • Pricing, Reimbursement and Access
    • Regulation
    • Government Affairs
    • Trump Administration
  • Therapy Areas
    • Dermatologicals
    • Oncology
    • Neurological
    • Rare Diseases
    • Hematology
    • Cardio Vascular
    • Diabetes
    • Cell And Gene Therapy
  • Conferences
    • JPM Healthcare Conference
    • ESMO
    • ASCO
    • ASH
    • EULAR
    • AAIC
    • EASD
    • Forthcoming Events
  • Ones to Watch
  • About
  • Contact
  • Newsletter
  • Sign inSubscribe
Subscribe
  • Home
  • New survey reinforces link between asthma and hay fever

New survey reinforces link between asthma and hay fever

1 June 2008

The latest Ipsos MORI Asthma UK survey, this year part funded by Merck Sharp & Dohme, the local subsidiary of US drug major Merck & Co, found that over two thirds (67%) of the 1,235 respondents diagnosed with asthma also suffered from symptoms of allergic rhinitis (hay fever) including runny nose, sneezing or itchy or red eyes. In addition, 72% of those said their asthma became worse when they experienced allergic rhinitis symptoms. These findings support the increasing recognition that asthma and allergic rhinitis are associated conditions.

Asthma and allergic rhinitis commonly co-exist and both cause inflammation of the airway. Previous research has reported that at least 50% of asthma patients also suffer from allergic rhinitis. Research also shows that the presence of allergic rhinitis increases the risk of asthma attacks and emergency hospitalization. However, 65% of survey respondents with allergic rhinitis symptoms said that their health care professional (doctor, nurse or pharmacist) had never discussed the condition's impact on asthma control.

For the majority of people surveyed (84%), symptoms were most severe during the spring or summer months, when pollen levels are high and hay fever is more prominent. However, 20% of respondents experience allergic rhinitis symptoms all year round, suggesting that people with asthma need to regularly monitor their symptoms.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Try before you buy

 

Free

7 day trial access

Take a Free Trial
  • All the news that moves the needle in pharma and biotech
  • Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
  • Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



More ones to watch >


Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news






Today's issue

Ascletis posts encouraging Phase II data for oral obesity drug
Pharmaceutical
Ascletis posts encouraging Phase II data for oral obesity drug
9 December 2025
Pharmaceutical
GSK ends synthetic lethality pact with Ideaya
9 December 2025
Pharmaceutical
Kallyope advances elismetrep after mid-stage migraine win
9 December 2025
Biotechnology
Prospects for Priligy as first mover CAR-T therapy for lymphoblastic leukemia in China
9 December 2025
Biotechnology
Lunsumio data shows potential in earlier lymphoma treatment lines
9 December 2025
Generics
AAM applauds House introduction of Skinny Labeling Bill
9 December 2025
Biotechnology
Cell and gene therapy investments shift as budgets tighten
9 December 2025

Company Spotlight

Evaxion Biotech
A clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies.




The Pharma Letter

39-43 Putney High Street, Putney
London, SW15 1SP
United Kingdom

  • About us
  • Contact
  • Subscribe
  • Sponsorship/advertising


  • Terms and Conditions
  • Privacy Policy
  • Twitter
  • Linkedin

Copyright © The Pharma Letter 2025   |   Headless Content Management with Blaze